Serum Metabolomic Signatures Predict Tumor Recurrence After Resection or Ablation in Patients with Early-stage Hepatocellular Carcinoma

Name: Serum Metabolomic Signatures Predict Tumor Recurrence After Resection or Ablation in Patients with Early-stage Hepatocellular Carcinoma
Creator: Hiroaki Kanzaki
Published: 2025-08-06T15:32:41.326Z
Keywords: Hepatocellular Carcinoma, Liver Disease

Kanzaki, Hiroaki; Arvind, Ashwini; Ahmed, Fouzia; Fujiwara, Naoto; Hoshida, Yujin; Singal, Amit

doi:10.17632/4yrvg9jp6t.1

Serum Metabolomic Signatures Predict Tumor Recurrence After Resection or Ablation in Patients with Early-stage Hepatocellular Carcinoma

Published: 6 August 2025| Version 1 | DOI: 10.17632/4yrvg9jp6t.1

Contributors:

Hiroaki Kanzaki, Ashwini Arvind, Fouzia Ahmed, Naoto Fujiwara, Yujin Hoshida, Amit Singal

Description

We generated serum metabolome profiles in patients with early-stage hepatocellular carcinoma (BCLC stage 0/A) who achieved complete response to surgical resection or local ablation at University of Texas Southwestern Medical Center and Parkland Health between 2015 and 2023. Normalized abundance of 19 unique metabolites was determined using ultra high-performance liquid chromatography/tandem mass spectrometry (UHPLC/MS/MS) performed by Metabolon, Inc.

Files

Institutions

University of Texas Southwestern Medical Center at Dallas

Serum Metabolomic Signatures Predict Tumor Recurrence After Resection or Ablation in Patients with Early-stage Hepatocellular Carcinoma

Description

Files

Institutions

Categories

Licence